Perioperative adjuvant biotherapy in high-risk resected cutaneous melanoma: The results of 5 years of follow-up

Melanoma Research

Volumn 17, Issue 5, 2007, Pages 310-315

  Elias, Elias George ^a   Zapas, John L ^a   Beam, Sandra L ^a   Culpepper, William J ^a  

^a Weinberg Cancer Institute   (United States)

Author keywords

Biotherapy; Melanoma; Perioperative adjuvant

Indexed keywords

ALPHA2B INTERFERON; PARACETAMOL; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HIGH RISK BEHAVIOR; HUMAN; LIVER TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MELANOMA; NAUSEA; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REPEATED DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 34648847333     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282c3a72a     Document Type: Article

References (26)

1. Duhra P, Ilchyshyn A. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol 1991; 16:303-305.
2. Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, et al. BCG immunotherapy of malignant melanoma: summary of a seven year experience. Ann Surg 1974; 180:635-640.
3. Yao T-J, Meyers M, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2-Keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 1999; 5:77-82.
4. Wolchok JD, Weber JS, Houghton AN, Livingston PO. Melanoma vaccines. In: Balch CM, Houghton AN, Soong S-J, editors. Cutaneous melanoma. St Louis, Missouri: Quality Medical Publishing, Inc.; 2003. pp. 645-656.
5. Brocker EB, Zwadlo G, Suter L, Brune M, Sorg C. Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. Cancer Immunol Immunother 1978; 25:81-86.
6. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma. Possible involvement of TNF alpha and IL-1 alpha. Int J Cancer 2000; 85:182-187.
7. Summer WC, Foraker AG. Spontaneous regression of human melanoma. Clin Exp Stud 1997; 13:79-81.
8. Rosenberg SA. Keynote address: perspectives on the use of interleukin-2 in cancer treatment. Cancer J Sci Am 1997; 3 (Suppl):S2-S6.
9. Kirkwood JM. Pharmacology of cancer biotherapeutics. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 461-471.
10. Brunda MJ, Bellantoni D, Sulich V. In-vivo antitumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987; 40:365-371.
11. Cameron RB, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 1988; 48:5810-5817.
12. Iigo M, Sakurai M, Tamura T, Saijo N, Hoshi A. In-vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 1988; 48:260-264.
13. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon alpha 2b in advanced human malignancies. Lancet 1990; 335:1509-1512.
14. Ratain MJ, Priest ER, Janisch L, Vogelzang NJ. A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer 1993; 71:2371-2376.
15. Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995; 13:1110-1122.
16. American Joint Committee on Cancer. Melanoma of the skin. In: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, editors. Cancer staging manual. 6th ed. New York: Springer; 2002. pp. 209-217.
17. Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, et al. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988; 48:2561-2567.
18. Sosman JA, Kohler PC, Hank J, Moore KH, Bechhof R, Storer B, et al. Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Nat Cancer Inst 1988; 80: 60-63.
19. Stein RC, Malkovska V, Morgan S, Galazka A, Aniszewski C, Roy SE, et al. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. Br J Cancer 1991; 63:275-278.
20. Perez EA, Scudder SA, Meyers FA, Tanaka MS, Paradise C, Gandara DR. Weekly 24-h continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study. J Immunother 1991; 10:57-62.
21. Lindemann A, Hoffken K, Schmidt RE, Diehl V, Kloke O, Gamm H, et al. A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother 1989; 28:275-281.
22. Kokoschka EM, Trautinger F, Knobler RM, Pohl-Markl H, Micksche M. Long-term adjuvant therapy of high-risk malignant melanoma with interferon alpha 2b. J Invest Dermatol 1990; 95 (Suppl):S193-S197.
23. Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, et al. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res 1990; 50:185-192.
24. + cells in cancer patients receiving recombinant interleukin 2. Cancer Res 1988; 48:6597-6602.
25. Ettinghausen SE, Lipford EH III, Mule JJ, Rosenberg SA. Recombinant interleukin 2 stimulates in-vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol 1985; 135:3623-3635.
26. + regulatory T-cells through a STAT-dependent mechanism and induces the expression of these cells in vivo. Blood 2006; 108:1571-1779.